116 related articles for article (PubMed ID: 2518674)
1. Technical aspects of isolation extremity perfusion: experimental studies and clinical experience.
Ghussen F; Krüger I
J Invest Surg; 1989; 2(4):487-96. PubMed ID: 2518674
[TBL] [Abstract][Full Text] [Related]
2. The limit of hyperthermic strain on skeletal muscle tissue during regional perfusion.
Ghussen F; Isselhard W
Res Exp Med (Berl); 1984; 184(2):115-23. PubMed ID: 6433411
[TBL] [Abstract][Full Text] [Related]
3. [Hyperthermic isolation perfusion of the extremities in malignant melanomas and soft tissue sarcomas].
Tonak J; Hohenberger W; Göhl J
Chirurg; 1984 Aug; 55(8):499-504. PubMed ID: 6488994
[No Abstract] [Full Text] [Related]
4. The effect of age on outcomes after isolated limb perfusion for advanced extremity malignancies.
Smith HG; Wilkinson MJ; Smith MJF; Strauss DC; Hayes AJ
Eur J Cancer; 2018 Sep; 100():46-54. PubMed ID: 29940423
[TBL] [Abstract][Full Text] [Related]
5. Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: feasibility and reproducibility in a multi-institutional Hellenic collaborative study.
Lasithiotakis K; Economou G; Gogas H; Ioannou C; Perisynakis K; Filis D; Kastana O; Bafaloukos D; Decatris M; Catodritis N; Frangia K; Papadakis G; Magarakis M; Tsoutsos D; Chrysos E; Chalkiadakis G; Zoras O
Oncol Rep; 2010 Apr; 23(4):1077-83. PubMed ID: 20204294
[TBL] [Abstract][Full Text] [Related]
6. Kinetics of melphalan leakage during hyperthermic isolation perfusion in melanoma of the limb.
Rauschecker HF; Foth H; Michaelis HC; Horst F; Gatzemeier W; Willenbrock C; Voth E; Kahl GF
Cancer Chemother Pharmacol; 1991; 27(5):379-84. PubMed ID: 1998997
[TBL] [Abstract][Full Text] [Related]
7. [Regional cytostatic perfusion of the extremities in patients with malignant melanoma and soft tissue sarcoma--therapeutic applications and results].
Eichfeld U; Gläser A; Schneider G; Kraus J; Pauer HJ; Schwarz I
Zentralbl Chir; 1993; 118(2):63-8. PubMed ID: 7682024
[TBL] [Abstract][Full Text] [Related]
8. Hyperthermic regional perfusion using membrane- instead of bubble-oxygenators. An experimental and clinical study.
van Os J; Schraffordt Koops H; Oldhoff J; Wildevuur CR
J Cardiovasc Surg (Torino); 1989; 30(4):523-32. PubMed ID: 2777859
[TBL] [Abstract][Full Text] [Related]
9. [Isolated limb perfusion with tumor necrosis factor for malignancies of the limbs].
Abu-Abid S; Gutman M; Lev D; Inbar M; Chaitchik S; Sorkine P; Rudick V; Meller I; Klausner JM
Harefuah; 1996 Oct; 131(7-8):227-32, 296, 295. PubMed ID: 8940515
[TBL] [Abstract][Full Text] [Related]
10. [Technic of isolated perfusion of the extremities. Experience with 171 cases].
Aigner K; Schwemmle K
Langenbecks Arch Chir; 1983; 359(2):113-22. PubMed ID: 6681855
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxics and hyperthermic perfusion: a preliminary study.
Tonak J; Hermanek P; Banz H; Groitl H
Cancer Treat Rev; 1979 Jun; 6 Suppl():135-41. PubMed ID: 498167
[No Abstract] [Full Text] [Related]
12. Value of continuous leakage monitoring with radioactive iodine-131-labeled human serum albumin during hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
van Ginkel RJ; Limburg PC; Piers DA; Koops HS; Hoekstra HJ
Ann Surg Oncol; 2002 May; 9(4):355-63. PubMed ID: 11986187
[TBL] [Abstract][Full Text] [Related]
13. The role of regional chemotherapy in the management of extremity soft tissue malignancies.
Smith HG; Hayes AJ
Eur J Surg Oncol; 2016 Jan; 42(1):7-17. PubMed ID: 26382102
[TBL] [Abstract][Full Text] [Related]
14. Hyperthermic isolated limb perfusion. The switch from Steinmann pins to Omni-tract assisted isolation.
Stamatiou D; Ioannou CV; Kontopodis N; Michelakis D; Perisinakis K; Lasithiotakis K; Zoras O
J Surg Res; 2017 Jun; 213():147-157. PubMed ID: 28601307
[TBL] [Abstract][Full Text] [Related]
15. [Tumor necrosis factor α and melfalan-based hyperthermic isolated limb perfusion in locally advanced extremity soft tissue sarcomas and melanomas].
Alegre JF; Duarte M; Sureda González M; Bretcha Boix P; Dussan C; Ballester A; Crespo A; Brugarolas Masllorens A
Cir Esp; 2012 Feb; 90(2):114-20. PubMed ID: 22225611
[TBL] [Abstract][Full Text] [Related]
16. Patient- and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities.
Klaase JM; Kroon BB; van Geel BN; Eggermont AM; Franklin HR; Hart GA
Am J Surg; 1994 Jun; 167(6):618-20. PubMed ID: 8209941
[TBL] [Abstract][Full Text] [Related]
17. [Isolated hyperthermic perfusion of the extremities with cytostatic agents. A method of treatment in malignant melanoma and soft tissue sarcoma].
Kettelhack C; Schlag P
Dtsch Krankenpflegez; 1989 Sep; 42(9):597-601. PubMed ID: 2518209
[No Abstract] [Full Text] [Related]
18. Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon, and melphalan.
Vaglini M; Belli F; Ammatuna M; Inglese MG; Manzi R; Prada A; Persiani L; Santinami M; Santoro N; Cascinelli N
Cancer; 1994 Jan; 73(2):483-92. PubMed ID: 8293417
[TBL] [Abstract][Full Text] [Related]
19. Current uses of isolated limb perfusion in the clinic and a model system for new strategies.
Eggermont AM; de Wilt JH; ten Hagen TL
Lancet Oncol; 2003 Jul; 4(7):429-37. PubMed ID: 12850194
[TBL] [Abstract][Full Text] [Related]
20. [Value of isolation-perfusion of the limbs in melanomas and sarcomas].
Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Kroon B
Ann Chir; 1995; 49(1):9-12. PubMed ID: 7741477
[No Abstract] [Full Text] [Related]
[Next] [New Search]
